title: Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft.
abstract: Platinum based combination regimens are first-line treatment option in treatment of non-small cell lung cancer (NSCLC) but the clinical utility has been limited because of their toxicities. Many reports indicated that patients with tumors can benefit from adjuvant chemotherapy drugs. The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. In vivo SPC-A-1 xenograft model was established to evaluate antitumor activity and toxicity of HSS along or combination with DP. Evaluation indexes include the relative tumor proliferation rate, tumor growth inhibition rate, body weight, food consumption, hematological and biochemical analysis. HSS treatment showed inhibited tumor growth and increased tumor inhibition of DP treatment at doses of 250 mg/kg and 500 mg/kg. No significant toxicity was found in HSS-treated mice, but significant toxicity was found in DP-treated mice. HSS combination with DP could reduce toxicity of DP treatment by improving body weight and food consumption, and increasing the number of WBC and PLT, decreasing the level of ALT, AST and BUN. HSS combined with DP treatment has additive effect which contributes to enhance tumor growth inhibition of DP treatment and attenuated effect which contributes to reduce toxicity of DP treatment. These findings indicate potential benefit for use of HSS adjuvant chemotherapy for NSCLC treatment.
authors.affiliation: Shandong Academy of pharmaceutical Sciences, Ji'nan, Shandong 250101, China. Electronic address: jiayupingygs@163.com.
authors.forename: Yuping
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Shandong Laboratory Animal Center, Shandong Academy of Medical Science, Ji'nan 250002, China. Electronic address: zhoudongshun@163.com.
authors.forename: Dongshun
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Shandong Academy of pharmaceutical Sciences, Ji'nan, Shandong 250101, China.
authors.forename: Qingwen
authors.initials: Q
authors.lastname: Jia
authors.affiliation: Cancer Hospital of Qindao Haisheng Co., Ltd., Qingdao 266031, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Ying
authors.affiliation: Cancer Hospital of Qindao Haisheng Co., Ltd., Qingdao 266031, China.
authors.forename: Shuntai
authors.initials: S
authors.lastname: Chen
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D000077143:Docetaxel; D004357:Drug Synergism; D005247:Feeding Behavior / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008819:Mice, Nude; D010940:Plant Proteins / Q000627:therapeutic use*; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
chemical_list: D010940:Plant Proteins; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
keywords: Additive effect; Antitumor activity; Cisplatin; Docetaxel; HSS; Toxicity